Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
- Authors:
- Autor USP: NAHAS, WILLIAM CARLOS - FM
- Unidade: FM
- DOI: 10.1016/S1470-2045(18)30860-X
- Subjects: NEOPLASIAS PROSTÁTICAS; METÁSTASE NEOPLÁSICA; NEOPLASIAS ÓSSEAS; ESTEROIDES; ANDRÓGENOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Lancet oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 20, n. 3, p. 408-419, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SMITH, Matthew et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, v. 20, n. 3, p. 408-419, 2019Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30860-X. Acesso em: 27 dez. 2025. -
APA
Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., et al. (2019). Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology, 20( 3), 408-419. doi:10.1016/S1470-2045(18)30860-X -
NLM
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X -
Vancouver
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Nahas WC. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial [Internet]. Lancet oncology. 2019 ; 20( 3): 408-419.[citado 2025 dez. 27 ] Available from: https://doi.org/10.1016/S1470-2045(18)30860-X - Histologic Inflammatory Changes on the Prostatic Gland Due to Immunosuppression for Kidney Transplantation
- Transplante renal
- Diagnosis of antibody-mediated rejeiction through early protocol biopsies in sensitized patients
- Rituximab in a B cell-driven regimen for the treatment of recurrent membranoproliferative glomerulonephritis after kidney transplantation
- Donor Transmission Intestinal Carcinoma After Kidney Transplantation: Case Report
- Revascularization of Living-Donor Kidney Transplant With Multiple Arteries: Long-term Outcomes Using the Inferior Epigastric Artery
- Critical points and potential pitfalls of outbreak of IMP-1-producing carbapenem-resistant Pseudomonas aeruginosa among kidney transplant recipients: a case-control study
- Performance of two methods of carbapenem-resistant Enterobacterales surveillance on a kidney transplant ward: selective culture of and real-time PCR directly from rectal swabs
- Robotic-assisted approaches to urachal carcinoma: a comprehensive systematic review of the safety and efficacy outcomes
- Experiência pioneira: primeiro caso de doação renal pareada no Brasil
Informações sobre o DOI: 10.1016/S1470-2045(18)30860-X (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
